Removal of residual colonic ciprofloxacin in the rat by activated charcoal entrapped within zinc-pectinate beads

Khoder, Mouhamad; Tsapis, Nicolas; Domergue-Dupont, Valérie; Gueutin, Claire

doi:10.1016/j.ejps.2010.06.018

Cited by 50 publications

(27 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tablets or capsules of activated carbon are still used today in many countries as an over-the-counter drug for diarrhea, indigestion, and flatulence. Activated charcoal administration may therefore improve the detrimental effects of microbiota dysbiosis by binding itself to potential toxins secreted in the digestive tract [133]. Further studies on activated charcoal potential effectiveness on psychiatric symptomatology are warranted.…”

Section: Activated Carbonmentioning

confidence: 99%

The “psychomicrobiotic”: Targeting microbiota in major psychiatric disorders: A systematic review

Fond

Boukouaci

Chevalier

et al. 2015

Pathologie Biologie

179

127

View full text Add to dashboard Cite

Section: Activated Carbonmentioning

confidence: 99%

The “psychomicrobiotic”: Targeting microbiota in major psychiatric disorders: A systematic review

Fond

Boukouaci

Chevalier

et al. 2015

Pathologie Biologie

179

127

View full text Add to dashboard Cite

“…An alternate means of inactivating antibiotics, the use of adsorbents targeted to the colon, could overcome this disadvantage. Indeed, it has been shown in vitro and in vivo in animal models that activated charcoal targeted to the colon was able to reduce exposure of the microbiota to fluoroquinolones during treatments (12)(13)(14). However, whether this approach could also work with broad-spectrum cephalosporins, which are currently a major driver of bacterial resistance to antibiotics (15), has not yet been tested.…”

mentioning

confidence: 99%

Oral DAV131, a Charcoal-Based Adsorbent, Inhibits Intestinal Colonization by β-Lactam-Resistant Klebsiella pneumoniae in Cefotaxime-Treated Mice

Grall

Massias

Nguyễn

et al. 2013

Antimicrob Agents Chemother

View full text Add to dashboard Cite

f Antibiotics excreted into the intestinal tract, such as broad-spectrum cephalosporins, disrupt the indigenous microflora, affect colonization resistance (CR), and promote intestinal colonization by resistant bacteria. We tested whether oral DAV131, a charcoal-based adsorbent, would prevent colonization by a cefotaxime (CTX)-resistant Klebsiella pneumoniae strain (PUG-2) in CTX-treated mice. Mice received CTX, saline, CTX and DAV131, or saline and DAV131 for 3 days before oral challenge with 10 6 CFU of PUG-2. The fecal CTX concentrations and counts of PUG-2 were assayed. Fecal CTX disappeared when DAV131 was given concomitantly with CTX (P < 0.05), and the area under the curve of PUG-2 fecal density was significantly reduced (P < 0.01). In conclusion, reducing intestinal antibiotic exposure with DAV131 may reduce colonization by resistant strains during treatment compared to treatment with CTX only. This might open new possibilities for decreasing the impact of antibiotics on the intestinal microbiota during treatments.

show abstract

“…Consequently, activated charcoal may be useful in microbe-induced neurobehavioral disorders, including ASD. A few studies suggest activated charcoal suppresses the growth of antibiotic-resistant intestinal bacteria (Khoder et al, 2010;Grall et al, 2013). However, similar to antibiotic treatments, it is likely that any beneficial effects of this intervention will be short-lived, and disease symptomology will return upon cessation of this therapy.…”

mentioning

confidence: 99%

Microbiome Disturbances and Autism Spectrum Disorders

2015

View full text Add to dashboard Cite

Autism spectrum disorders (ASDs) are considered a heterogenous set of neurobehavioral diseases, with the rates of diagnosis dramatically increasing in the past few decades. As genetics alone does not explain the underlying cause in many cases, attention has turned to environmental factors as potential etiological agents. Gastrointestinal disorders are a common comorbidity in ASD patients. It was thus hypothesized that a gut-brain link may account for some autistic cases. With the characterization of the human microbiome, this concept has been expanded to include the microbiota-gut-brain axis. There are mounting reports in animal models and human epidemiologic studies linking disruptive alterations in the gut microbiota or dysbiosis and ASD symptomology. In this review, we will explore the current evidence that gut dysbiosis in animal models and ASD patients correlates with disease risk and severity. The studies to date have surveyed how gut microbiome changes may affect these neurobehavioral disorders. However, we harbor other microbiomes in the body that might impact brain function. We will consider microbial colonies residing in the oral cavity, vagina, and the most recently discovered one in the placenta. Based on the premise that gut microbiota alterations may be causative agents in ASD, several therapeutic options have been tested, such as diet modulations, prebiotics, probiotics, synbiotics, postbiotics, antibiotics, fecal transplantation, and activated charcoal. The potential benefits of these therapies will be considered. Finally, the possible mechanisms by which changes in the gut bacterial communities may result in ASD and related neurobehavioral disorders will be examined.

show abstract

Removal of residual colonic ciprofloxacin in the rat by activated charcoal entrapped within zinc-pectinate beads

Cited by 50 publications

References 32 publications

The “psychomicrobiotic”: Targeting microbiota in major psychiatric disorders: A systematic review

The “psychomicrobiotic”: Targeting microbiota in major psychiatric disorders: A systematic review

Oral DAV131, a Charcoal-Based Adsorbent, Inhibits Intestinal Colonization by β-Lactam-Resistant Klebsiella pneumoniae in Cefotaxime-Treated Mice

Microbiome Disturbances and Autism Spectrum Disorders

Contact Info

Product

Resources

About